TY - JOUR
T1 - Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection
T2 - Safety, antiviral activity, resistance, and pharmacokinetics
AU - Lawitz, Eric
AU - Sulkowski, Mark
AU - Jacobson, Ira
AU - Kraft, Walter K.
AU - Maliakkal, Benedict
AU - Al-Ibrahim, Mohamed
AU - Gordon, Stuart C.
AU - Kwo, Paul
AU - Rockstroh, Juergen Kurt
AU - Panorchan, Paul
AU - Miller, Michelle
AU - Caro, Luzelena
AU - Barnard, Richard
AU - Hwang, Peggy May
AU - Gress, Jacqueline
AU - Quirk, Erin
AU - Mobashery, Niloufar
N1 - Funding Information:
This study was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Whitehouse Station, NJ. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The study sponsor and the authors were responsible for the study design, protocol, statistical analysis plan, and data analysis. The sponsor performed the statistical analysis. The authors had unrestricted access to the data, were integral to the development of the manuscript, and decided to submit the paper for publication. All authors approved the final draft of the manuscript.
PY - 2013/9
Y1 - 2013/9
N2 - Vaniprevir is a competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease that has potent anti-HCV activity in preclinical models. This placebo-controlled dose-ranging study assessed the safety, tolerability, and antiviral efficacy of vaniprevir monotherapy in patients with genotype 1 chronic HCV infection. Treatment-naive and treatment-experienced non-cirrhotic adult patients with baseline HCV RNA >106IU/ml were randomized to receive placebo or vaniprevir at doses of 125mg qd, 600mg qd, 25mg bid, 75mg bid, 250mg bid, 500mg bid, and 700mg bid for 8days. Forty patients (82.5% male, 75% genotype 1a) received at least one dose of placebo or vaniprevir. After 1week of vaniprevir, the decrease in HCV RNA from baseline ranged from 1.8 to 4.6log10IU/ml across all treatment groups, and there was a greater than dose-proportional increase in vaniprevir exposure at doses above 75mg bid. The most commonly reported drug-related adverse events (AEs) were diarrhea (n=5) and nausea (n=5). No pattern of laboratory or ECG abnormalities was observed, all AEs resolved during the study, and there were no discontinuations due to AEs. No serious AEs were reported. Resistance-associated amino acid variants were identified at positions R155 and D168 in patients infected with genotype 1a virus. Vaniprevir monotherapy demonstrated potent antiviral activity in patients with chronic genotype 1 HCV infection, and was generally well tolerated with no serious AEs or discontinuations due to AEs. Further development of vaniprevir, including studies in combination with other anti-HCV agents, is ongoing.
AB - Vaniprevir is a competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease that has potent anti-HCV activity in preclinical models. This placebo-controlled dose-ranging study assessed the safety, tolerability, and antiviral efficacy of vaniprevir monotherapy in patients with genotype 1 chronic HCV infection. Treatment-naive and treatment-experienced non-cirrhotic adult patients with baseline HCV RNA >106IU/ml were randomized to receive placebo or vaniprevir at doses of 125mg qd, 600mg qd, 25mg bid, 75mg bid, 250mg bid, 500mg bid, and 700mg bid for 8days. Forty patients (82.5% male, 75% genotype 1a) received at least one dose of placebo or vaniprevir. After 1week of vaniprevir, the decrease in HCV RNA from baseline ranged from 1.8 to 4.6log10IU/ml across all treatment groups, and there was a greater than dose-proportional increase in vaniprevir exposure at doses above 75mg bid. The most commonly reported drug-related adverse events (AEs) were diarrhea (n=5) and nausea (n=5). No pattern of laboratory or ECG abnormalities was observed, all AEs resolved during the study, and there were no discontinuations due to AEs. No serious AEs were reported. Resistance-associated amino acid variants were identified at positions R155 and D168 in patients infected with genotype 1a virus. Vaniprevir monotherapy demonstrated potent antiviral activity in patients with chronic genotype 1 HCV infection, and was generally well tolerated with no serious AEs or discontinuations due to AEs. Further development of vaniprevir, including studies in combination with other anti-HCV agents, is ongoing.
KW - Dose-ranging
KW - Efficacy
KW - Monotherapy
KW - Pharmacokinetics
KW - Safety
UR - http://www.scopus.com/inward/record.url?scp=84884550531&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884550531&partnerID=8YFLogxK
U2 - 10.1016/j.antiviral.2013.05.015
DO - 10.1016/j.antiviral.2013.05.015
M3 - Article
C2 - 23747481
AN - SCOPUS:84884550531
SN - 0166-3542
VL - 99
SP - 214
EP - 220
JO - Antiviral Research
JF - Antiviral Research
IS - 3
ER -